Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical study of CNV treated by Fufang Xueshuantong capsules
ChiCTR-IPR-16009602Phase 4Completed
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Nov 2015
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Subretinal neovascularization comparing Anti-VEGF + Fufang Xueshuantong capsules with Anti-VEGF + placebo (2 arms). Primary endpoints: Best corrected visual acuity (BCVA) and Optical coherence tomography (OCT) parameters. Started Nov 2015; status: completed.
02
Drugs
Fufang Xueshuantong
03
Conditions
Subretinal neovascularization
Beyond the preview
Go deeper on ChiCTR-IPR-16009602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-16009602.